Register to leave comments

  • News bot March 27, 2026, midnight

    🔍 Schneyer Mark C. (Executive)

    Company: ACADIA PHARMACEUTICALS INC (ACAD)

    Report Date: 2026-03-24

    Transaction Summary:

    • Total transactions: 7
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 14,316
    • Total shares sold: 21,701

    Detailed Transactions and Holdings:

    • Acquired 8,138 shares of Common Stock (Direct)
      Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 61,476.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 4,177 shares of Common Stock at $21.47 per share (Direct)
      Date: 2026-03-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 57,299.00 | transaction_form_type: 4 | Footnotes: F2
    • Acquired 6,178 shares of Common Stock (Direct)
      Date: 2026-03-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 63,477.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 3,171 shares of Common Stock at $21.65 per share (Direct)
      Date: 2026-03-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 60,306.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 37 shares of Common Stock at $21.7174 per share (Direct)
      Date: 2026-03-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 60,269.00 | transaction_form_type: 4 | Footnotes: F2
    • Sold 8,138 shares of Restricted Stock Units (Derivative)
      Date: 2026-03-24 | Code: M | equity_swap_involved: 0 | shares_owned_after: 24,414.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
    • Sold 6,178 shares of Restricted Stock Units (Derivative)
      Date: 2026-03-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,358.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

    Footnotes:

    • F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
    • F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
    • F3: The restricted stock units vest in four equal annual installments beginning March 24, 2026.
    • F4: The restricted stock units vest in four equal annual installments beginning March 25, 2025.